Business Description
Camurus AB
ISIN : SE0007692850
Total Employee Number:
308Compare
Compare
Traded in other countries / regions
CAMX.Sweden0RD1.UK7CA.GermanyCAMRF.USA IPO Date
2017-10-13Description
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 35.21 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.12 | |||||
Interest Coverage | 136.25 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 36.85 | |||||
Beneish M-Score | -3.06 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 31.2 | |||||
3-Year EBITDA Growth Rate | 119.1 | |||||
3-Year EPS without NRI Growth Rate | 140.9 | |||||
3-Year FCF Growth Rate | 91.4 | |||||
3-Year Book Growth Rate | 58.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 60.77 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 39.96 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.45 | |||||
9-Day RSI | 16.2 | |||||
14-Day RSI | 17.27 | |||||
3-1 Month Momentum % | 15.09 | |||||
6-1 Month Momentum % | -9.18 | |||||
12-1 Month Momentum % | 0.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.57 | |||||
Quick Ratio | 11.28 | |||||
Cash Ratio | 9.72 | |||||
Days Inventory | 290.13 | |||||
Days Sales Outstanding | 78.76 | |||||
Days Payable | 177.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -0.86 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.13 | |||||
Operating Margin % | 35.87 | |||||
Net Margin % | 30.45 | |||||
EBITDA Margin % | 39.96 | |||||
FCF Margin % | 36.07 | |||||
OCF Margin % | 42.51 | |||||
ROE % | 16.94 | |||||
ROA % | 15.01 | |||||
ROIC % | 65.66 | |||||
3-Year ROIIC % | 261.47 | |||||
ROC (Joel Greenblatt) % | 184.02 | |||||
ROCE % | 21 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 45.77 | |||||
Forward PE Ratio | 33.88 | |||||
PE Ratio without NRI | 45.77 | |||||
Shiller PE Ratio | 3505.28 | |||||
Price-to-Owner-Earnings | 40.29 | |||||
PS Ratio | 13.92 | |||||
PB Ratio | 6.98 | |||||
Price-to-Tangible-Book | 7.01 | |||||
Price-to-Free-Cash-Flow | 38.5 | |||||
Price-to-Operating-Cash-Flow | 32.7 | |||||
EV-to-EBIT | 31.21 | |||||
EV-to-Forward-EBIT | 31.65 | |||||
EV-to-EBITDA | 30.3 | |||||
EV-to-Forward-EBITDA | 31.25 | |||||
EV-to-Revenue | 12.11 | |||||
EV-to-Forward-Revenue | 10.44 | |||||
EV-to-FCF | 33.48 | |||||
Price-to-GF-Value | 0.65 | |||||
Price-to-Projected-FCF | 4.34 | |||||
Price-to-Median-PS-Value | 0.53 | |||||
Price-to-Graham-Number | 3.78 | |||||
| Price-to-Net-Current-Asset-Value | 7.57 | |||||
| Price-to-Net-Cash | 9.25 | |||||
Earnings Yield (Greenblatt) % | 3.2 | |||||
FCF Yield % | 2.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CAMRF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Camurus AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 238.443 | ||
| EPS (TTM) ($) | 1.205 | ||
| Beta | 1.3142 | ||
| 3-Year Sharpe Ratio | 0.68 | ||
| 3-Year Sortino Ratio | 2.68 | ||
| Volatility % | 38.59 | ||
| 14-Day RSI | 17.27 | ||
| 14-Day ATR ($) | 0.445908 | ||
| 20-Day SMA ($) | 57.71 | ||
| 12-1 Month Momentum % | 0.48 | ||
| 52-Week Range ($) | 54 - 71 | ||
| Shares Outstanding (Mil) | 59.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Camurus AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Camurus AB Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 07:00 | In 134 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 133 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-15 | In 20 days | ||
| Second quarter earnings results for 2026 | 2026-07-15 | In 20 days | ||
| General meeting for 2026 | 2026-05-28 17:00 | 63.30 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 14:00 | 63.30 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 63.30 (+0.00%) | ||
| Annual report for 2025 | 2026-04-29 | 63.30 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-13 14:00 | 57.85 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-13 | 57.85 (+0.00%) |
Show
Entries
Camurus AB Frequently Asked Questions
What is Camurus AB(CAMRF)'s stock price today?
The current price of CAMRF is $54.00. The 52 week high of CAMRF is $71.00 and 52 week low is $54.00.
When is next earnings date of Camurus AB(CAMRF)?
The next earnings date of Camurus AB(CAMRF) is 2026-07-15.
Does Camurus AB(CAMRF) pay dividends? If so, how much?
Camurus AB(CAMRF) does not pay dividend.
Guru Commentaries on OTCPK:CAMRF
No articles.
Press Release
Articles on Camurus AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers